According to a filing with the exchange, the reported profit decreased YoY due to lower operating profitability and increase in depreciation for Line 3 in Spokane.
The revenue went up 17% on yearly basis to Rs 2,229 crore against Rs 1,901 crore in the same time period a year ago on the back of strong performance across all business segments, with CDMO Sterile Injectables delivering particularly robust growth.
The total income jumped 18% to Rs 2,249 crore against Rs 1,913 crore in Q1FY26. The other income for Q1’FY27 includes grant income of Rs 5.6 crore for Line 3, which shall continue for more than 20 years and upto 30 years.
Also Read | Gold prices rise Rs 6,600/10 gram in 3 days; silver jumps Rs 16,200/kg ahead of US inflation data. Big rally brewing?
Radiopharma: Radiopharmaceuticals Q1’FY27 revenue grew by 19% to Rs. 322 Cr. and EBITDA for the period stood at Rs. 110 Cr. EBITDA margins decreased YoY due to unavailability of certain SPECT products. By H2’FY27, all the SPECT Radiopharmaceutical products are expected to be available. Radiopharmacy Q1’FY27 revenue grew by 17% YoY to Rs. 700 Cr. on the back of an increase in volume from certain PET products. EBITDA for the period grew by 19% to Rs. 12 Cr.
Allergy Immunotherapy : As the sole supplier of Venom in the US, we are expanding the overall market by increasing customer awareness. In Q1’FY27, revenues grew by 18% to Rs. 214 Cr., driven by strong growth in the US & outside US markets. EBITDA grew by 5% to Rs. 66 Cr. EBITDA margins reduced YoY due to lower production.
CDMO Sterile Injectables : Q1’FY27 revenue grew by 34% to Rs. 496 Cr. due to incremental revenue from Line 3. EBITDA for the period stood at Rs. 45 Cr. EBITDA margins were lower YoY due to negligible third-party revenues & higher operating expenses including incremental remediation cost at Montreal facility.
CRDMO : In Q1’FY27, the Drug Discovery business revenue grew by 8% to Rs. 174 Cr. EBITDA for the period grew by 43% to Rs. 45 Cr. EBITDA margins expanded by 630 basis points to 26%. In the API business, revenue for Q1’FY27 stood at Rs. 135 Cr. EBITDA for the period stood at Rs. 19 Cr. Revenue and EBITDA margins decreased YoY due to the industry wide pricing pressure.
Also Read | BSE shares to join rival NSE's benchmark index Nifty 50. What this means for shareholders
Generics : In Q1’FY27, the Generics business revenue grew by 4% to Rs. 173 Cr on the back of launch of 2 new products. EBITDA for the period stood at Rs. 4 Cr. EBITDA margins decreased YoY due to change in product mix. Looking ahead, we are preparing to launch multiple products in FY27 to drive revenue growth & profitability.
Proprietary Novel Drugs : The global clinical trials for our lead programs, Phase I/II trial for JBI -802 for Essential Thrombocythemia (ET) and other Myeloproliferative Neoplasms (MPN) and Phase I trial for JBI -778 for non-small cell lung cancer (NSCLC), Adenoid Cystic Carcinoma and high-grade Glioma are actively enrolling patients and progressing in line with our expectations
While sharing the Vision 2030, the company expects the revenue to reach 2x from FY24 to FY30. EBITDA margin is expected between 23% to 25% by FY30.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)
Subscribe to ET Prime and read the Economic Times ePaper Online.and Sensex Today.
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)
Subscribe to ET Prime and read the Economic Times ePaper Online.and Sensex Today.
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price